CHE vs ZBH
Chemed Corp. vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | CHE | ZBH |
|---|
| AI Score |
64
|
66
|
| Price |
$541.60
|
$97.89
|
| P/E Ratio |
26.96×
|
23.54×
|
| ROE |
27.1%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.4%
|
69.9%
|
| Debt / Equity |
0.35×
|
0.59×
|
| Dividend Yield |
0.4%
|
1.0%
|
| RSI (14) |
53.7
|
59.8
|
| Beta |
0.511
|
0.462
|
| Expected Upside |
+0.2%
|
+0.6%
|
AI Committee View
Current Innellis committee reasoning for CHE versus ZBH.
ZBH leads by 2 points.
ZBH scores 66/100 (Buy) versus CHE at 64/100 (Buy).
CHE Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 26.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.4% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 26.2 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is price-to-book of 1.4x is a discount to asset value. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical